Yahoo
Morningstar

Morningstar

Apr 24, 2026

CRISPR Therapeutics AG: Positive Long-Term Outlook for Crispr Therapeutics as Gene Editing Portfolio Makes Progress

Symbols

CRSP

Sector(s)

Healthcare

Rating

Current Price

51.63

Fair Value

Economic Moat

Stewardship

Summary

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transf

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Upgrade
Mobilize your Website
View Site in Mobile | Classic
Share by: